Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

19.89
+1.075.69%
Pre-market: 19.890.00000.00%08:42 EDT
Volume:2.96M
Turnover:58.52M
Market Cap:3.87B
PE:-39.72
High:20.00
Open:18.90
Low:18.85
Close:18.82
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:91.34M
Volume Ratio:1.59
T/O Rate:3.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:3.15
PE(LYR):-12.28

Loading ...

Legend Biotech Announces Late-Breaking Oral Presentation at Eha 2026 Showcasing Initial Phase 1 in Vivo CAR-T Data With Lb2501 in Non-Hodgkin Lymphoma (Nhl)

THOMSON REUTERS
·
Jun 02

Legend Biotech: No Dose-Limiting Toxicities, Serious Adverse Events, or Neurotoxicity Reported

THOMSON REUTERS
·
Jun 02

Legend Biotech: 100% Orr (6/6) Observed in Dose Level 2 Cohort, Including Cr Rate of 83.3% (5/6) in Patients With Relapsed/ Refractory Nhl

THOMSON REUTERS
·
Jun 02

Legend's experimental cell therapy shows promise in blood cancer patients

Reuters
·
Jun 02

Legend Biotech: Data Demonstrates Robust in Vivo CAR-T Expansion Without Lymphodepleting Chemotherapy or Bridging Therapy

THOMSON REUTERS
·
Jun 02

Legend Biotech presents first-in-human LB2102 results in solid tumors

TIPRANKS
·
Jun 02

Genscript Highlights Legend Biotech’s New CAR-T Data in Oncology Programs

TIPRANKS
·
Jun 01

Legend Points Carvykti Toward Use in Earlier Setting, RBC Says

MT Newswires Live
·
Jun 01

Legend Biotech Showcases First-in-Human LB2102 Data and Strengthens CARVYKTI Profile at ASCO 2026

TIPRANKS
·
Jun 01

Legend Biotech says Phase 1 LB2102 CAR-T posts 28.6% response rate in relapsed solid tumors at higher doses

Reuters
·
Jun 01

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

GlobeNewswire
·
Jun 01

Oppenheimer Remains a Buy on Legend Biotech (LEGN)

TIPRANKS
·
Jun 01

J&J Mastered Cancer Biotech Deals on the Cheap. Can it Stay on the Cutting Edge? -- Heard on the Street -- WSJ

Dow Jones
·
May 28

GENSCRIPT BIO Surges Over 5% Following Partner Legend Biotech's ASCO 2026 Research Presentations

Stock News
·
May 27

A Look At Legend Biotech (LEGN) Valuation After Its Strong Q1 2026 Revenue And Narrower Net Loss

Simply Wall St.
·
May 22

Legend Biotech to Showcase New CAR-T Data at ASCO 2026

TIPRANKS
·
May 22

Legend Biotech presents preliminary Phase 1 LB2102 data in small-cell lung cancer at ASCO 2026

Reuters
·
May 22

Legend Biotech Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Krystal Biotech (KRYS)

TIPRANKS
·
May 18

HHLR's Q1 Portfolio: Capital Flows to Semiconductor Sector, PDD and Alibaba Remain Top Holdings

Stock News
·
May 16